Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34,455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.
Liu J, Zhang B, Su Y, Qin G, Kong X, Mo Y, Zhang R, Jiang W. Liu J, et al. Among authors: zhang b, zhang r. Radiother Oncol. 2023 Oct;187:109815. doi: 10.1016/j.radonc.2023.109815. Epub 2023 Jul 20. Radiother Oncol. 2023. PMID: 37480994 Clinical Trial.
Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.
Liao S, Zhang B, Su Y, Pan Y, Zhang J, Ye Z, Zhang R, Kong X, Qin G, Mo Y, Ruan X, Liu J, Gan C, Dai J, Zhang R, Luo G, Liao X, Jiang W. Liao S, et al. Among authors: zhang b, zhang r, zhang j. Strahlenther Onkol. 2024 Feb 7. doi: 10.1007/s00066-024-02201-1. Online ahead of print. Strahlenther Onkol. 2024. PMID: 38324078
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.
Dong YY, Xiang C, Lu JX, Su YX, Pan YF, Cai R, Zhang RJ, He ZK, Liu ML, Huang H, Bai X, Tang HY, Shi YH, Wang Y, Jiang W. Dong YY, et al. Among authors: zhang rj. Strahlenther Onkol. 2016 Jun;192(6):394-402. doi: 10.1007/s00066-016-0970-3. Epub 2016 May 23. Strahlenther Onkol. 2016. PMID: 27215563 English.
Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
Mo Y, Pan Y, Zhang B, Zhang J, Su Y, Liu Z, Luo M, Qin G, Kong X, Zhang R, Pan Y, Liang Y, Wang D, Wei Y, Chen H, Jiang W. Mo Y, et al. Among authors: zhang b, zhang r, zhang j. Front Immunol. 2024 Jan 3;14:1298418. doi: 10.3389/fimmu.2023.1298418. eCollection 2023. Front Immunol. 2024. PMID: 38239359 Free PMC article. Clinical Trial.
34,455 results
You have reached the last available page of results. Please see the User Guide for more information.